These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25189357)

  • 21. [Cervical cancer: vaccination against cancer. Updates on vaccination and early detection].
    Deutsches Grünes Kreuz e.V
    Kinderkrankenschwester; 2015 Dec; 34(12):458. PubMed ID: 26946633
    [No Abstract]   [Full Text] [Related]  

  • 22. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Implementation of HPV vaccination in Germany].
    Schreckenberger C; Kaufmann AM; Schneider A
    Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
    [No Abstract]   [Full Text] [Related]  

  • 25. HPV vaccination: unanswered questions remain.
    Linhares IM; Witkin SS
    BJOG; 2015 Jan; 122(1):118. PubMed ID: 25208474
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues in human papillomavirus vaccination in adolescents.
    Moscicki AB; Smith JS
    J Adolesc Health; 2008 Oct; 43(4 Suppl):S1-4. PubMed ID: 18809142
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.
    Mikolajczyk RT; Horn J; Damm O; Kaufmann AM; Kretzschmar ME
    J Natl Cancer Inst; 2012 Jan; 104(2):163; author reply 163-4. PubMed ID: 22232131
    [No Abstract]   [Full Text] [Related]  

  • 29. HPV Vaccine Confers Multisite Protection.
    Cancer Discov; 2015 Jun; 5(6):OF1. PubMed ID: 25904655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer.
    Berkhof J; Bogaards JA
    Future Oncol; 2010 Dec; 6(12):1817-21. PubMed ID: 21142854
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of vaccination against HPV infection to prevent cervical cancer in France.
    Ribassin-Majed L; Hill C; Lounes R
    Public Health; 2015 Jan; 129(1):78-81. PubMed ID: 25544659
    [No Abstract]   [Full Text] [Related]  

  • 33. Characterization of Immunoglobulin A/G Responses During 3 Doses of the Human Papillomavirus-16/18 ASO4-Adjuvanted Vaccine.
    Gonçalves AK; Giraldo PC; Farias KJ; Machado PR; Costa AP; de Souza LC; Crispim JC; Eleutério J; Witkin SS
    Sex Transm Dis; 2016 May; 43(5):335-9. PubMed ID: 27100772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women.
    Sonawane K; Nyitray AG; Nemutlu GS; Swartz MD; Chhatwal J; Deshmukh AA
    JAMA Netw Open; 2019 Dec; 2(12):e1918571. PubMed ID: 31880792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus.
    Pellegrino P; Carnovale C; Perrone V; Antoniazzi S; Pozzi M; Clementi E; Radice S
    Eur J Epidemiol; 2013 Aug; 28(8):705-7. PubMed ID: 23864234
    [No Abstract]   [Full Text] [Related]  

  • 38. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
    De Carvalho N; Teixeira J; Roteli-Martins CM; Naud P; De Borba P; Zahaf T; Sanchez N; Schuind A
    Vaccine; 2010 Aug; 28(38):6247-55. PubMed ID: 20643092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.